+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 83 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying cizutamig in patients with thyroid eye disease TED to evaluate its safety, tolerability, how the body processes the drug pharmacokinetics, its effects on the body pharmacodynamics, immune response, and preliminary clinical activity. This Phase 1b, open-label, multicenter trial focuses on patients diagnosed with Graves Disease who have active, moderate to severe TED. Participants will receive cizutamig dosed according to the study protocol. The study does not include a placebo group, and all participants receive the experimental drug. The trial aims to observe the bodys reaction to cizutamig and collect detailed data on drug levels and immune responses throughout treatment. During the study, participants will be monitored for adverse events and changes in vital signs such as body temperature, heart rate, respiratory rate, blood pressure, and pulse oximetry. Electrocardiogram ECG parameters and laboratory safety tests including serum chemistry and blood counts will also be assessed from baseline through 12 months. The research team will track pharmacokinetic parameters including peak concentration, clearance, and half-life of the drug. Participants will attend regular visits for assessments and safety monitoring over the course of one year.

Age: 18Years - 75YearsAll GendersPhase 1
14 locations
E

Actively Recruiting

Researchers are evaluating the safety and preliminary effectiveness of TQB2930 combined with chemotherapy, with or without bevacizumab, in people who have HER2-abnormally expressed, locally advanced or metastatic colorectal cancer that cannot be removed by surgery. This phase IbII clinical trial aims to better understand how these treatments work together to target cancer cells expressing the HER2 protein. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and includes adult participants from 18 to 75 years old. Participants are randomly assigned to receive either TQB2930 injection plus chemotherapy and bevacizumab injection or TQB2930 injection plus chemotherapy alone. Chemotherapy drugs include oxaliplatin and capecitabine tablets or irinotecan hydrochloride injection with capecitabine tablets. TQB2930 targets HER2 proteins on tumor cells to reduce their growth, while bevacizumab works by blocking blood vessel formation that feeds tumors. Treatment continues until disease progression or other criteria are met. Throughout the study, participants undergo assessments such as measuring tumor response, monitoring adverse events, and collecting blood samples to analyze drug levels and immune responses. The main outcomes include determining the recommended dose for phase 2, safety monitoring from consent until 28 days after the last dose, and tracking objective response rates for up to 24 months. Secondary outcomes include survival rates, duration of response, and drug behavior in the body. Participants are monitored regularly during treatment and follow-up periods lasting up to two years.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
31 locations
P

Actively Recruiting

Researchers are evaluating TQB2102, an antibody-drug conjugate designed to target Human Epidermal Growth Factor Receptor 2 HER2 in patients with locally advanced or metastatic non-small cell lung cancer who have HER2 gene abnormalities. This Phase 2 study aims to assess the effectiveness and safety of TQB2102, which combines targeted antibody action with a potent drug payload that is normally too toxic for general use. Participants receive TQB2102 through intravenous infusion every three weeks, with each treatment cycle lasting 21 days. Some participants will receive TQB2102 alone, while others will receive TQB2102 combined with Benmelstobart, another intravenous drug targeting programmed death ligand-1 PD-L1. Both treatments are given over multiple cycles to evaluate their effects. During the study, participants will be closely monitored through various assessments including measuring tumor response over up to eight months, tracking survival, and recording any adverse events from the start of treatment until 28 days after the last dose. Researchers will also check for immune responses to the drug at several points during and after treatment. The total participation may last up to 18 months to gather comprehensive safety and effectiveness data.

Age: 18Years - 75YearsAll GendersPhase 2
25 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
E

Actively Recruiting

Researchers are investigating the effect of baxdrostat, a drug taken once daily, compared to a placebo on lowering 24-hour average systolic blood pressure SBP in adults with uncontrolled hypertension. This condition means their blood pressure remains high despite using two or more antihypertensive medications from different classes without diuretics. The study is a Phase IIIb, randomized, double-blind, placebo-controlled trial conducted across multiple centers in China. Participants will first go through a screening period lasting up to 4 weeks, followed by a 4-week run-in phase where they take a placebo. After this, they will be randomly assigned to receive either baxdrostat 2 mg or placebo orally once daily for 12 weeks while continuing their background blood pressure medications without dose changes, except in cases of low blood pressure symptoms. Rescue therapy is allowed if blood pressure becomes dangerously high, excluding certain diuretics. After treatment, a 2-week safety follow-up will be conducted. The total participation time is approximately 22 weeks. During the study, participants will have their blood pressure monitored, including ambulatory 24-hour average SBP as the primary outcome at week 12. Other assessments include nighttime and daytime blood pressure, seated blood pressure, and safety monitoring for adverse events, including special focus on potassium and sodium levels. Adherence to medication will be tracked, and safety will be overseen by a dedicated committee. Participants health status will be followed through the end of the study period.

Age: 18Years +All GendersPhase 3
51 locations
S

Actively Recruiting

Researchers are evaluating zorifertinib as a first-line treatment for patients with advanced non-small cell lung cancer NSCLC that has mutations in the EGFR gene and has spread to the central nervous system CNS. This prospective study involves multiple centers and compares the survival benefits and safety of zorifertinib to other similar drugs called EGFR tyrosine kinase inhibitors EGFR-TKIs. The study aims to better understand how well zorifertinib works and its clinical value in this patient group. Participants are divided into three groups those receiving first-line zorifertinib who meet criteria of the EVEREST study, those receiving zorifertinib but not meeting EVEREST criteria, and those receiving other anti-tumor drugs chosen by their doctors excluding zorifertinib. The EVEREST study is an open-label trial comparing zorifertinib to gefitinib or erlotinib. Treatments are given as prescribed by clinicians, with monitoring of safety and dosage adjustments as needed. During the study, participants will be followed for up to 36 months, with assessments every 8 weeks to measure overall survival, progression-free survival, intracranial progression, response rates, and adverse events. Researchers will track dose changes and monitor safety outcomes over time. The study collects clinical data to evaluate the effectiveness and tolerability of the treatments in patients with EGFR-mutant advanced NSCLC and CNS metastases.

Age: 18Years +All Genders
34 locations
A

Actively Recruiting

Healthy Volunteer

Chronic kidney disease CKD involves damage to the kidneys structure or function and affects a significant portion of the population in China, with a prevalence of 10.8%. CKD not only leads to severe kidney failure requiring treatments like dialysis but also raises the risk of cardiovascular diseases, placing a heavy burden on individuals and the healthcare system. This research aims to improve understanding of CKD occurrence, progression, treatment, prognosis, and risk factors in the Chinese population through a large-scale, real-world observational study. The study is a multi-center, prospective observational registry involving participants from various centers across mainland China. It collects and integrates standardized data to efficiently analyze CKD patterns and outcomes. The study includes both CKD patients and individuals with risk factors such as hypertension, diabetes, or hyperlipidemia, as well as healthy participants, to allow broad representation and subgroup analysis. The study is designed to cover a large sample size and account for potential loss to follow-up. Participants will be observed over up to 5 years to monitor the development of CKD in non-CKD individuals and the progression of disease in those with CKD. Researchers will track changes in kidney function, albuminuria levels, and composite endpoints including disease progression and mortality. Data collection includes clinical assessments and laboratory measurements to evaluate disease markers and outcomes. The study offers long-term monitoring to better understand CKD dynamics and inform prevention and control strategies.

Age: 18Years +All Genders
8 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations

1-10 of 83

1